On this page
- Two procedures that share a word
- Why the difference is not a technicality
- What the aHSCT evidence in multiple sclerosis shows
- What the MSC evidence in multiple sclerosis shows
- How the substitution happens in practice
- The same pattern in other conditions
- Questions that separate the two
- What this means for reading the rest of this site
- Frequently asked questions
- Requesting a medical evaluation
This is the most consequential confusion in stem cell marketing, and almost nobody explains it. Haematopoietic stem cell transplantation and mesenchymal stromal cell infusion are different procedures, with different cells, different risks and entirely different evidence — and the evidence for the first is routinely used to sell the second.
Two procedures that share a word
Both get called “stem cell treatment”. That is where the similarity ends.
Autologous haematopoietic stem cell transplantation, written aHSCT, uses blood-forming stem cells to rebuild an immune system that has first been destroyed or heavily suppressed by chemotherapy. It is an inpatient hospital procedure run by haematology units, and it carries a genuine risk of death.
Mesenchymal stromal cell infusion gives connective-tissue-derived cells, usually into a vein, over an hour or two, with no conditioning chemotherapy and no immune ablation. It is an outpatient procedure. It is what clinics sell.
Why the difference is not a technicality
In aHSCT, the cells are not the treatment in the way people assume. The chemotherapy is what resets the misbehaving immune system; the transplanted cells are what rescues the patient from the chemotherapy. Remove the conditioning and you have not performed a gentler version of the same thing — you have performed something else.
An MSC infusion does not reset anything. Its proposed mechanism is modulation of an immune environment, not replacement of an immune system.
So a trial result for aHSCT says nothing about what an MSC infusion will do, even in the same disease, in the same patient.
What the aHSCT evidence in multiple sclerosis shows
This is a real body of evidence and it deserves to be described accurately rather than borrowed.
A randomised trial compared non-myeloablative aHSCT against continued disease-modifying therapy in relapsing-remitting MS — Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy.
A meta-analysis has pooled aHSCT studies in MS — Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis — alongside phase II trial data — Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial — and further efficacy and safety analysis — Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis.
The population that benefits most is fairly specific: younger patients with aggressive relapsing disease and active inflammation, treated in specialist centres. It is not a general MS treatment, and it is not offered at outpatient clinics.
What the MSC evidence in multiple sclerosis shows
Separately, and much more recently, MSCs have been studied in MS in their own right. This evidence is real too, and it is at a much earlier stage.
A randomised double-blind trial examined intrathecal MSCs in progressive MS — Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind Trial — and related work has looked at MSC-neural progenitor therapy — Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS.
Other studies have measured neurophysiological outcomes — Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis — and cerebrospinal fluid biomarkers — Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers.
Note what these trials mostly deliver: cells into the spinal fluid, not into a vein. An intravenous infusion is a third thing again, and the least studied of the three.
How the substitution happens in practice
It is rarely a lie. It is usually a sequence of true sentences arranged so a reader draws a false conclusion.
A page says stem cells have been shown to slow MS progression in randomised trials — true, of aHSCT. The next paragraph describes the clinic’s infusion protocol — also true. Nothing false has been written and the reader now believes something false.
The tell is the missing noun. Ask which cells, by which route, in which trial. A clinic that answers precisely is describing its own evidence; one that says “stem cells” is borrowing someone else’s.
The same pattern in other conditions
Cerebral palsy is the clearest parallel. A meta-analysis has specifically distinguished cord blood infusions from mesenchymal stromal cells — An updated meta-analysis of umbilical cord blood to treat cerebral palsy: distinguishing cord blood infusions from mesenchymal stromal cells — which exists because the two were being pooled as though they were one intervention.
Earlier work reviewed stem cell interventions in cerebral palsy generally — Stem Cell Interventions for People With Cerebral Palsy: Systematic Review With Meta-Analysis.
In cardiology, a Cochrane review assessed stem cell treatment after heart attack — Stem cell treatment for acute myocardial infarction — and Cochrane reviews are worth reading precisely because they are unenthusiastic by design.
Questions that separate the two
Take these to any clinic discussing a neurological or autoimmune condition with you.
- Are you proposing haematopoietic or mesenchymal cells?
- Is there conditioning chemotherapy? If not, this is not the procedure in the MS transplant trials.
- By what route — intravenous, intrathecal, intra-articular?
- Which published trial used that cell type, by that route, in my condition?
- Is this an inpatient hospital procedure or an outpatient infusion?
The answers are not hard for an honest clinic to give, and the main treatment page lists a longer set worth taking to anyone you are considering.
What this means for reading the rest of this site
Every clinical page here states which cell type and which route the evidence it cites actually used. Where a condition has evidence for one procedure and not another, the page says so rather than blurring them.
See multiple sclerosis for how this plays out in that specific condition, and what the evidence levels mean for the grading used throughout.
MSC therapy describes the cells most of this site concerns.
Frequently asked questions
Are HSCT and MSC therapy the same thing?
No. Different cells, different procedures, different risks and separate evidence bases. Only the phrase “stem cell treatment” is shared.
Which one has evidence in multiple sclerosis?
Both, but for different things. aHSCT has randomised trials and a meta-analysis in aggressive relapsing disease. MSC evidence is earlier and mostly intrathecal rather than intravenous.
Can a clinic offer aHSCT?
Not as an outpatient infusion. It requires conditioning chemotherapy and inpatient haematology care, with real mortality risk.
Why does the distinction matter to me?
Because evidence quoted for one procedure may be used to justify a different one you are actually being offered. Ask which cells and which route.
Is an intravenous MSC infusion studied in MS?
Less than the intrathecal route. Most published MSC work in MS delivers cells into the spinal fluid, which is a different procedure again.
What is the single best question to ask?
“Which published trial used this cell type, by this route, in my condition?” The precision of the answer tells you most of what you need.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.